Biomarker: | FGF3 amplification + ER positive |
---|---|
Cancer: | HER2 Negative Breast Cancer |
Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) + gedatolisib (PF-05212384) (mTOR inhibitor, PI3K inhibitor, mTORC1 inhibitor, mTORC2 inhibitor) |
Direction: | Sensitive |